Bard Surgical Mesh – Not Worth the Risks Says FDA

The C.R. Bard Company of New Jersey, is one of nine synthetic surgical mesh manufacturers whose products are used in women to treat stress urinary incontinence and pelvic organ prolapse. Avaulta is the best known Bard product, and despite the fact that the U.S. Food and Drug Administration (FDA) has received several thousand reports of complications from synthetic mesh, the Avaulta surgical mesh system is still on the market.

Of particular concern are the “arms” that are made of a form of plastic, a synthetic polypropylene mesh. Once implanted in the body, they grow into tissue and can adhere to organs, making them very difficult to remove. Complications may include erosion into surrounding tissue and organs, pain, nerve damage, migration of the mesh, and hardening of the plastic. The arms can be problematic to remove and, in some cases, surgeons will opt to leave the arms behind, sentencing the patient to a lifetime of pain and possibly disability. Other Bard products include Avaulta Plus, Avaulta Solo, and Avaulta Biosynthetic. Once the mesh is out, a woman may need reconstructive surgery to put damaged tissues back in place, such as reconstructing the vagina, the rectum, or the pelvic floor.

There is no wonder why the FDA suggested in its July 13, 2011 Public Health Notification that the risks associated with synthetic Avaulta mesh may not be worth the benefit.

At Farah & Farah, our Jacksonville synthetics mesh injury attorneys understand it is difficult to discuss your pelvic surgery complications. That is why we have assigned compassionate and understanding women to discuss your case and your injuries. A statute of limitations does apply so we have opened the door to a complimentary consultation. You will not have to pay anything for us to take your case unless we secure an award on your behalf. Our number is (800) 533-3555.